Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Orchestra BioMed Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Orchestra BioMed Holdings, Inc.’s stock price such as:

• Orchestra BioMed Holdings, Inc.’s current stock price and volume
• Why Orchestra BioMed Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for OBIO from analysts
• OBIO’s stock price momentum as measured by its relative strength

About Orchestra BioMed Holdings, Inc. (OBIO)

Before we jump into Orchestra BioMed Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

Want to learn more about Orchestra BioMed Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Orchestra BioMed Holdings, Inc..

Orchestra BioMed Holdings, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Orchestra BioMed Holdings, Inc.’s stock price was $3.980.

Orchestra BioMed Holdings, Inc. is down 0.25% from its previous closing price of $3.990.

During the last market session, Orchestra BioMed Holdings, Inc.’s stock traded between $3.843 and $4.060. Currently, there are approximately 62.72 million shares outstanding for Orchestra BioMed Holdings, Inc..

Orchestra BioMed Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Orchestra BioMed Holdings, Inc. Stock Price History

Orchestra BioMed Holdings, Inc.’s (OBIO) price is currently down 7.76% so far this month.

During the month of July, Orchestra BioMed Holdings, Inc.’s stock price has reached a high of $4.470 and a low of $3.555.

Over the last year, Orchestra BioMed Holdings, Inc. has hit prices as high as $5.424 and as low as $2.200. Year to date, Orchestra BioMed Holdings, Inc.’s stock is down 4.1%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Orchestra BioMed Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Orchestra BioMed Holdings, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Orchestra BioMed Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Orchestra BioMed Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Orchestra BioMed Holdings, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Orchestra BioMed Holdings, Inc. (OBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Orchestra BioMed Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Orchestra BioMed Holdings, Inc. has a weighted four-quarter relative price strength of 1.34%, which translates to a Momentum Score of 58 and is considered to be Average.

Want to learn more about how Orchestra BioMed Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Orchestra BioMed Holdings, Inc. Stock Price: Bottom Line

As of July 31, 2026, Orchestra BioMed Holdings, Inc.’s stock price is $3.980, which is down 0.25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Orchestra BioMed Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.